motor neurone disease or Duchenne muscular dystrophy) or relapsing or intermittent (for example, myasthenia gravis). Patients with these disorders may develop severe and unexpected deterioration of ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

Dystrophin's isoforms are thought to contribute variably to neuropsychiatric disorders, behavioral disorders, and ...

U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support licensure Advisory Committee meeting scheduled for July 30, 2025 Mid-cycle ...

Phil Lambert, Ph.D., chief scientific officer of Satellos Bioscience Inc., explains the mechanism of action of the company's experimental Duchenne muscular dystrophy drug, SAT-3247, and the thinking ...

Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. This clinical trial report ...

LONDON, ON, May 19, 2025 /CNW/ - On May 25, Canadians are walking, running, and rolling in support of the 30th annual Walk to Defeat Duchenne, the country's only national event dedicated to ...

We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...

Avidity has been given the go-ahead by the FDA to request accelerated approval of delpacibart braxlosiran—potentially the ...

Regenxbio (RGNX) stock in focus as the company shares promising trial data for its RGX-202 gene therapy for Duchenne muscular ...

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from ...

"Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.